Abstract
Activation of the innate and adaptive immune systems represents a promising strategy for defeating cancer. However, during tumor progression, cancer cells battle to shift the balance from immune activation to immunosuppression. Critical sites of this battle are regions of intratumoral hypoxia, and a major driving force for immunosuppression is the activity of hypoxia-inducible factors, which regulate the transcription of large batteries of genes in both cancer and stromal cells that block the infiltration and activity of cytotoxic T lymphocytes and natural killer cells, while stimulating the infiltration and activity of regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. Targeting hypoxia-inducible factors or their target gene products may restore anticancer immunity and improve the response to immunotherapies.
Original language | English (US) |
---|---|
Pages (from-to) | 73-83 |
Number of pages | 11 |
Journal | Physiology |
Volume | 36 |
Issue number | 2 |
DOIs | |
State | Published - 2021 |
Keywords
- CTLA4
- HIF-1α
- HIF-2α
- Oxygen
- PD1
- PDL1
ASJC Scopus subject areas
- Physiology